PGI23 USING DISCRETE CHOICE EXPERIMENTS (DCE)TO MEASURE PREFERENCES FOR TREATMENT OPTIONS: AN APPLICATION TO GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)  by Kilonzo, MM & Vale, L
are reduced, and the percentage of patients requiring surgery
decreases. Inﬂiximab should be used on a maintenance schedule
rather than episodically (i.e.: treatment of ﬂares) in order to
optimize treatment outcomes.
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OBJECTIVES: It has been recommended that due to a lack of
evidence, screening for hereditary hemochromatosis should be
rejected and instead, further research is warranted. This study
builds on a published quantitative synthesis of evidence and
assesses the expected value of perfect information (EPVI) as an
upper bound of value for further research. Implications of
modelling results and EVPI for both Bayesian and Frequentist
decision makers with different cost-effectiveness thresholds are
discussed. METHODS: Expected value of information both for
the decision, for single and for groups of parameters are calcu-
lated. Population EVPI was based on an inﬁnite time horizon for
the target cohort of 30 years old Germans. RESULTS: A Fre-
quentist decision maker can be assumed to reject screening based
on a lack of high quality evidence of cost-effectiveness at thresh-
olds between 50,000 and 100,000 EUR/LYG. In contrary, for a
Bayesian with a cost-effectiveness threshold of 50,000 or beyond
100,000 EUR/LYG evidence may be sufﬁcient: The former will
probably reject, the latter pursue population screening. The
overall costs of uncertainty for the decision are comparatively
small: the total expected value of perfect information at a cost-
effectiveness threshold of 50,000 EUR/LYG was calcu-lated to be
approximately 1 million EUR. Uncertainty about compliance
had the highest expected value of partial perfect information of
approx. 200,000 EUR. CONCLUSION: Further research on
genetics in health care should include the issue of patient com-
pliance. Frequentist decision making incurs costs in terms of
expected health forgone. Yet the Frequentist decision is more
stable: Given the deterioration of cost-effectiveness ratios in past
economic studies, a Bayesian decision maker with a threshold of
EUR 50,000/LYG may have introduced screening years ago while
a Frequentist decision maker would always have rejected
it. Coverage with evidence development may bridge the gap
between both.
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OBJECTIVES: Certolizumab pegol, a PEGylated anti-TNFa
fragment, induced and maintained health-related quality of life
(HRQoL) at levels that are indicative of remission in patients
with active Crohn’s disease (CD) in the PRECiSE 2 trial
(Schreiber et al., 2005). HRQoL was assessed using the Inﬂam-
matory Bowel Disease Questionnaire (IBDQ), which evaluates
four domains: bowel symptoms (BS), systemic symptoms (SS),
emotional function (EF) and social function (SF). The SF-36 and
EQ-5D were administered and utility scores determined. A
strong relationship was documented recently between both
preference-based measures and the IBDQ scores in patients with
CD (Buxton et al., 2007). Using PRECiSE 2 data, this analysis
evaluated the correlations between changes in IBDQ scores and
changes in utility indexes derived from the EQ-5D and SF-6D in
patients with active CD. METHODS: EQ-5D and SF-6D utility
scores were derived using the established algorithms (Dolan
et al., 1995 and Brazier et al., 2002, respectively). The changes in
IBDQ domains and total score were paired to the changes in
utility scores between Weeks 0 and 26. Correlations between 405
(EQ-5D) and 375 (SF-6D) paired observations were calculated
using Spearman coefﬁcients. RESULTS: The strength of the asso-
ciation between changes in utility scores and IBDQ scores was
two to four times larger when using the EQ-5D (Spearman
coefﬁcients 0.48 [SF] to 0.58 [total score]) compared with
the SF-6D (Spearman coefﬁcients 0.13 [SF] to 0.23 [EF]). All
coefﬁcients were statistically signiﬁcant: p-values <0.0001 with
the EQ-5D and <0.0001 (EF) to 0.0151 (SF) with the SF-6D.
CONCLUSION: Changes in IBDQ scores were associated with
consistent changes in both EQ-5D and SF-6D utility scores in
patients with active CD. However, the magnitude of the correla-
tion coefﬁcients suggests that the EQ-5D is more sensitive to
HRQoL changes than the SF-6D in CD.
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OBJECTIVES: To identify the strength of the study participants’
preferences for the different treatments and outcomes of GORD
and to investigate whether these preferences differ between the
different arms of the REFLUX trial. METHODS: A qualitative
study and expert advice were used to identify four dimensions
related to the treatment and outcomes of care. These were:
frequency of troublesome symptoms, chance of serious compli-
cations, chance of undergoing surgery, and chance of needing life
long medication. The questionnaires were sent to participants in
the 4 arms of the REFLUX trial (randomised medical, ran-
domised surgical, prefer medical, prefer surgical). Data were
analysed using logistic regression techniques. RESULTS: The
most important dimension was serious complications, followed
by the chance of having surgery or receiving lifelong medication.
Suffering troublesome symptoms most days was least important.
There was no evidence that treatment group had any effect
on preferences for either ‘troublesome symptoms’ or ‘serious
complications’. However, preferences differed for ‘surgery’ and
‘lifelong medications’. CONCLUSION: The DCE aids the
interpretation of the clinical evidence by indicating the impor-
tance placed on type of treatment and a treatment’s ability to
resolve symptoms. The results of the analysis highlight the impor-
tance of quantifying the risk of serious complications and of
considering patient choice when decisions are made the types of
treatment to provide and the type of treatment to recommend.
GI DISORDERS—Patient Reported Outcomes
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OBJECTIVES: The short, self-administered Gastroesophageal
Reﬂux Disease (GERD) Symptom Frequency Questionnaire
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